JP2005515237A - 免疫無防備状態の個体群に用いる糖コンジュゲートワクチン - Google Patents

免疫無防備状態の個体群に用いる糖コンジュゲートワクチン Download PDF

Info

Publication number
JP2005515237A
JP2005515237A JP2003561504A JP2003561504A JP2005515237A JP 2005515237 A JP2005515237 A JP 2005515237A JP 2003561504 A JP2003561504 A JP 2003561504A JP 2003561504 A JP2003561504 A JP 2003561504A JP 2005515237 A JP2005515237 A JP 2005515237A
Authority
JP
Japan
Prior art keywords
antigen
vaccine
polysaccharide
type
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003561504A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005515237A5 (enExample
Inventor
ファットム，アリ，アイ．
ナソー，ロバート，ビー．
Original Assignee
ナビ バイオファーマシューティカルズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナビ バイオファーマシューティカルズ filed Critical ナビ バイオファーマシューティカルズ
Publication of JP2005515237A publication Critical patent/JP2005515237A/ja
Publication of JP2005515237A5 publication Critical patent/JP2005515237A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2003561504A 2001-09-19 2002-09-19 免疫無防備状態の個体群に用いる糖コンジュゲートワクチン Pending JP2005515237A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/955,585 US20030113350A1 (en) 2001-09-19 2001-09-19 Glycoconjugate vaccines for use in immune-compromised populations
PCT/US2002/029601 WO2003061558A2 (en) 2001-09-19 2002-09-19 Glycoconjugate vaccines for use in immune-compromised populations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010155473A Division JP2010265293A (ja) 2001-09-19 2010-07-08 免疫無防備状態の個体群に用いる糖コンジュゲートワクチン

Publications (2)

Publication Number Publication Date
JP2005515237A true JP2005515237A (ja) 2005-05-26
JP2005515237A5 JP2005515237A5 (enExample) 2006-01-12

Family

ID=25497036

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003561504A Pending JP2005515237A (ja) 2001-09-19 2002-09-19 免疫無防備状態の個体群に用いる糖コンジュゲートワクチン
JP2010155473A Pending JP2010265293A (ja) 2001-09-19 2010-07-08 免疫無防備状態の個体群に用いる糖コンジュゲートワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010155473A Pending JP2010265293A (ja) 2001-09-19 2010-07-08 免疫無防備状態の個体群に用いる糖コンジュゲートワクチン

Country Status (11)

Country Link
US (2) US20030113350A1 (enExample)
EP (1) EP1427442A4 (enExample)
JP (2) JP2005515237A (enExample)
KR (3) KR101090529B1 (enExample)
CN (1) CN1306958C (enExample)
CA (1) CA2460749C (enExample)
EA (1) EA006602B1 (enExample)
MX (1) MXPA04002624A (enExample)
NZ (1) NZ548453A (enExample)
WO (1) WO2003061558A2 (enExample)
ZA (1) ZA200402185B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10188609A (ja) * 1996-09-03 1998-07-21 Kwangju Electron Co Ltd 照明機器のランプ過熱防止装置及び方法
JP2010514817A (ja) * 2007-01-04 2010-05-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチンの製造方法
JP2011528710A (ja) * 2008-07-21 2011-11-24 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド β−１，６−グルコサミンオリゴ糖を合成するための方法および組成物
JP2015522692A (ja) * 2012-07-16 2015-08-06 ファイザー・インク 糖およびその使用
US10919956B2 (en) 2002-11-12 2021-02-16 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
JP2022546812A (ja) * 2019-08-27 2022-11-09 アロペックス・インコーポレイテッド 抗菌性ワクチン組成物
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020092987A1 (en) * 1998-09-05 2002-07-18 Taehee Cho Photo detect device using quantum dots and materialization method thereof
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
WO2004050846A2 (en) * 2002-12-02 2004-06-17 Biosynexus Incorporated Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines
JP5102487B2 (ja) * 2003-03-07 2012-12-19 ワイス・ホールディングズ・コーポレイション 院内感染に対する免疫化のための多糖ブドウ球菌表面付着因子キャリアタンパク質接合体
AU2011265368B9 (en) * 2004-09-22 2012-11-29 Biosynexus Incorporated Immunogenic composition
RU2402347C2 (ru) * 2004-09-22 2010-10-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
AU2005324448A1 (en) * 2005-01-10 2006-07-20 Glaxosmithkline Biologicals Sa Method of treating Staphylococcus aureus infection
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
FR2884830A1 (fr) 2005-04-25 2006-10-27 Sanofi Pasteur Sa Procede de production de souches de staphylococcus aureus surproductrices
PL3006458T3 (pl) * 2005-07-29 2018-05-30 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Zmutowane egzotoksyny Pseudomonas o zmniejszonej antygenowości
WO2007113222A2 (en) * 2006-03-30 2007-10-11 Glaxosmithkline Biologicals S.A. Immunogenic composition
FR2899110A1 (fr) * 2006-03-31 2007-10-05 Sanofi Pasteur Sa Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
JP5658564B2 (ja) * 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
WO2010014304A1 (en) * 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
HUE026855T2 (en) 2009-04-03 2016-07-28 Univ Chicago Compositions and methods related to protein a (spa) variants
WO2011041003A2 (en) 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
SI2445522T1 (sl) 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
MX373250B (es) 2009-09-30 2020-05-04 Glaxosmithkline Biologicals S A Star Conjugación de polisacáridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
BR112012010223A2 (pt) 2009-10-30 2016-12-06 Novartis Ag purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares
AU2010342872B2 (en) * 2010-01-19 2014-09-25 Universitatsklinikum Freiburg Enterococcal cell wall components and antibacterial use thereof
SG186290A1 (en) 2010-07-02 2013-01-30 Univ Chicago Compositions and methods related to protein a (spa) variants
CN102565354A (zh) * 2010-12-13 2012-07-11 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539726A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539708A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539702A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102565332A (zh) * 2010-12-13 2012-07-11 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102565336A (zh) * 2010-12-13 2012-07-11 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539704A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
WO2016091904A1 (en) 2014-12-10 2016-06-16 Glaxosmithkline Biologicals Sa Method of treatment
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
WO2023133143A1 (en) * 2022-01-05 2023-07-13 Bluewillow Biologics, Inc. Intranasal polysaccharide conjugate nanoemulsion vaccines and methods of using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10188609A (ja) * 1996-09-03 1998-07-21 Kwangju Electron Co Ltd 照明機器のランプ過熱防止装置及び方法
US10919956B2 (en) 2002-11-12 2021-02-16 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
JP2010514817A (ja) * 2007-01-04 2010-05-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチンの製造方法
JP2011528710A (ja) * 2008-07-21 2011-11-24 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド β−１，６−グルコサミンオリゴ糖を合成するための方法および組成物
US9474806B2 (en) 2008-07-21 2016-10-25 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
US10034927B2 (en) 2008-07-21 2018-07-31 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
US11123416B2 (en) 2008-07-21 2021-09-21 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
JP2015522692A (ja) * 2012-07-16 2015-08-06 ファイザー・インク 糖およびその使用
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
JP2022546812A (ja) * 2019-08-27 2022-11-09 アロペックス・インコーポレイテッド 抗菌性ワクチン組成物

Also Published As

Publication number Publication date
WO2003061558A2 (en) 2003-07-31
CN1638794A (zh) 2005-07-13
ZA200402185B (en) 2005-06-29
KR101214766B1 (ko) 2012-12-24
CA2460749C (en) 2012-10-23
WO2003061558A3 (en) 2003-09-12
KR101090529B1 (ko) 2011-12-08
EA200400448A1 (ru) 2004-12-30
EP1427442A4 (en) 2006-06-21
WO2003061558A9 (en) 2004-06-10
US20030113350A1 (en) 2003-06-19
CA2460749A1 (en) 2003-07-31
KR20080089527A (ko) 2008-10-06
KR20040070331A (ko) 2004-08-07
US20060188518A1 (en) 2006-08-24
NZ548453A (en) 2007-07-27
CN1306958C (zh) 2007-03-28
EP1427442A2 (en) 2004-06-16
MXPA04002624A (es) 2005-02-17
JP2010265293A (ja) 2010-11-25
US7449189B2 (en) 2008-11-11
KR20100044265A (ko) 2010-04-29
EA006602B1 (ru) 2006-02-24

Similar Documents

Publication Publication Date Title
US7449189B2 (en) Glycoconjugate vaccines for use in immune-compromised populations
AU2019215212B2 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2019215216B2 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
EA037500B1 (ru) Способы и композиции для иммунной защиты против внекишечной патогенной e. coli
WO1992016232A1 (en) Polysaccharide-protein conjugates
EP4512419A1 (en) Polyvalent pneumococcal polysaccharide conjugate vaccine component and application thereof
AU2002365253B2 (en) Glycoconjugate vaccines for use in immune-compromised populations
AU2002365253A1 (en) Glycoconjugate vaccines for use in immune-compromised populations
NZ531647A (en) Glycoconjugate vaccines for use in immune-compromised populations against Staphylococcal and Enterococcal infections
CN101443454A (zh) 多价脑膜炎球菌衍生化的多糖-蛋白质缀合物和疫苗
Lee Capsule and vaccine development
Naso et al. Polysaccharide conjugate vaccines for the prevention of gram-positive bacterial infections
RU2780425C2 (ru) Композиции neisseria meningitidis и способы
AU662141C (en) Polysaccharide-protein conjugates
Fattom et al. Vaccines for Staphylococcus aureus infections
Byrd Development of conjugate vaccines to protect pigs against swine pleuropneumonia induced by Actinobacillus pleuropneumoniae

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090515

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100708

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20100708